drugset / Trial / NCT05337774
Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury
Phase 1
Terminated
18 enrolled
Lantheus Biosciences Ltd.
Walter Reed National Military Medical Center · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The main objective of this interdisciplinary study is to develop an understanding of the molecular imaging features of blast-related mild traumatic brain injury (mTBI) in military personnel, while helping to establish assessment tools that may be of use in diagnosis, determining prognosis, and in future therapeutic clinical trials. Additionally, the objective is to evaluate feasibility of \[18F\]PI-2620 in the assessment TBI.
Timeline
- Start
- 2021-06-07
- Primary completion
- 2022-04-30
- Completion
- 2022-04-30
Outcome
Outcome not reported
Stopped (Business): “study funding period ended March 2022”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]PI-2620 | Diagnostic / imaging agent | 185 mbq | Intravenous |